SLC7A11 and tuberculosis: Based on these observations, it appears reasonable to determine whether specific xCT inhibitors, such as sulfasalazine (SASP) (86), an anti-inflammatory drug routinely used in clinical therapy, can be used as host-directed therapy (HDT) to boost host antimicrobial response during TB treatment.